WebPhone Number 917-607-0015. Pinteon Therapeutics focuses on the discovery and development of breakthrough therapeutics targeting Pin1. Pin1 acts as a central regulator in cancer development and growth as … WebPinteon Therapeutics has raised a total of $48.6M in funding over 4 rounds. Their latest funding was raised on Jan 11, 2024 from a Series B round. Pinteon Therapeutics has a …
Did you know?
WebApr 15, 2024 · The company's drug promotes recovery of function in patients suffering from acute neurologic injury, enabling doctors to treat brain diseases of alzheimer's and other central nervous system drugs effectively and improve episodic memory functions. Contact Information Website www.eippharma.com Ownership Status Privately Held (backing) WebFeb 1, 2024 · Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com....
WebPinteon Therapeutics - Funding, Financials, Valuation & Investors Oops! There was a problem! There was an unexpected issue while trying to process your request. Please refresh the page and try again. If the problem persists, please contact support. Refresh WebJun 24, 2024 · Pinteon will leverage Lonza's global manufacturing network, regulatory competence, extensive expertise in manufacturing monoclonal antibodies, and …
WebMar 7, 2024 · Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in … WebMar 18, 2024 · Pinteon Therapeutics. 2013-2024. Head Vice President, Neuroscience & Clinical Research. Pfizer. 2006-2024. Education. Doctor of Medicine. University of Miami Leonard M. Miller School of Medicine. Doctor of Philosophy - Cell Biology, Virology, Physical Chemistry. The Rockefeller University.
WebOct 28, 2024 · Most Recent Events. 28 Oct 2024 No recent reports of development identified for phase-I development in Neurodegenerative-disorders (In volunteers) in USA (IV, Infusion) 28 Jun 2024 Beth Israel Deaconess Medical Center licensed PNT 001 to Pinteon Therapeutics, prior to June 2024. 24 Jun 2024 Pinteon Therapeutics plans a clinical trial …
WebJan 21, 2024 · Footnotes. Declaration of interests: Author EJ’s spouse is an employee of, and owns stock options in, Epic. HZ, author, has served at scientific advisory boards … hougang cc study roomWebJan 26, 2024 · In September 2024, Pinteon began a Phase 1 safety and tolerability study of PNT001 in healthy adults. In the trial, 49 people received single doses of 33, 100, 300, … hougang cc worldcup scheduleWebPinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. The company reported promising Phase 1 safety data early in 2024 showing PNT001 was well-tolerated at dose levels that may ... hougang cc opening hoursWebOct 31, 2024 · Alzheimer’s is expected to affect 14 million Americans alone by 2050, making it a multi-billion-dollar market opportunity.. Pinteon was originally focused on developing … linkedin tableau certificationWebOct 31, 2024 · Alzheimer’s is expected to affect 14 million Americans alone by 2050, making it a multi-billion-dollar market opportunity.. Pinteon was originally focused on developing cancer therapies when it ... linkedin takedown requestWebDec 6, 2024 · Pinteon Therapeutics, Inc. Disclosed Value Value cannot be readily determined Listed Reason Equity Interest - Non-publicly traded entity ( e.g., stock, stock … hougang central post officeWebMar 7, 2024 · Pinteon Therapeutics is part of the Business Services industry, and located in Massachusetts, United States. Pinteon Therapeutics Location 1188 Centre St, Newton Center, Massachusetts, 02459, United States Description Read More Industry Business Services General Business Services Discover more about Pinteon Therapeutics linkedin tableau assessment answers